This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07104383 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 3 |
| Sponsor | Viking Therapeutics, Inc. |
| Enrollment | 1,100 participants |
| Design | Interventional, Randomized, Parallel, Masking: Triple |
| Conditions | Weight Loss |
| Interventions | VK2735 |
| Start | Jun 23, 2025 |
| Primary completion | Jul 1, 2027 |
| Study completion | Aug 1, 2027 |
| Results posted | Not yet |
| Registry last updated | Apr 7, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent change in body weight from baseline to Week 78 in body weight | 78 Weeks |
1 secondary outcome also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
